Study finds persistently high mortality in drug-resistant Gram-negative infections despite new antibiotics
By
Sameer S Kadri, MDa,b,c Send email to [email protected]
Summary
This retrospective cohort study examines whether mortality rates among patients with difficult-to-treat resistant (DTR) Gram-negative infections have changed since the introduction of newer, next-generation antibiotics in the USA. Despite the availability of these improved antibiotics, the study finds that mortality and the use of in-vitro discordant initial antibiotics remain unacceptably high. The research highlights that prompt recognition of both the pathogen and resistance phenotype is crucial for reducing mortality. A notable decrease in adjusted mortality over time was observed for Pseudomonas aeruginosa bloodstream infections, though this finding is considered hypothesis-generating due to the small cohort size.
Source
bskyStudy finds persistently high mortality in drug-resistant Gram-negative infections despite new antibioticsthelancet.comKey quotes
· 3 pulledDespite the availability of newer antibiotic agents, the estimated mortality and ongoing use of in-vitro discordant initial antibiotics remains unacceptably high among patients with DTR infections in US hospitals.
Prompt recognition of both the pathogen and resistance phenotype could be a crucial component in reducing mortality.
Although notable, the decrease over time in adjusted mortality for P aeruginosa bloodstream infections should be considered hypothesis-generating because the cohort of patients with such infections was small.
You might also wanna read
Stewardship / Resistance Scan for Mar 18, 2019
WHO Report: Antibiotic Resistance Growing Faster Than Expected, Causing 1.2 Million Annual Deaths
A new WHO report reveals that antibiotic resistance is growing at an alarming rate, with antimicrobial resistance already responsible for ap
Stewardship / Resistance Scan for Apr 02, 2020

Japan's bold experiment to curb antibiotic misuse has been a huge success. Could it work in the US?


Comments
Sign in to join the conversation.
No comments yet. Be the first.